S100B and Cognitive impairment: The presence of S100B at the level of CS100B ≥ 7.8 pg/mL was surprisingly detected in few patients in the NfT2DM group before COVID-19 (1.96%) and after COVID-19 (10.9%), which might be due not so much to their pharmacotherapy but to the absence of cognitive impairments.